News Releases

Microbix Hosts Ontario Premier Doug Ford & Team

Microbix Hosts Ontario Premier Doug Ford & Team

was pleased to host Government of Ontario candidates Premier Doug Ford (Etobicoke North riding) and local MPP Deepak Anand (Mississauga-Malton riding). During their site visit on the morning of February 27 — Ontario’s Provincial Election Day — our team had great conversations about how next-generation diagnostic tests can improve health outcomes for patients while also reducing healthcare costs.

read more
Microbix & API Ensuring Flu Tests Can Detect H5N1 Strain

Microbix & API Ensuring Flu Tests Can Detect H5N1 Strain

Microbix and American Proficiency Institute (API), a groundbreaking supplier of proficiency testing (“PT”) to over 20,000 clinical laboratories, announce the start of a pilot PT program to ensure that molecular diagnostic (“MDx”) assays can detect the emerging H5N1 strain of the Influenza A virus (“H5N1 Flu”).

read more
Microbix Schedules Release of Results for Q4 Fiscal 2024

Microbix Schedules Release of Results for Q4 Fiscal 2024

announces that it expects to file the financial statements and management disclosure and analysis for its fourth quarter of fiscal 2024 ended September 30, 2024 (“Q4 2024”) prior to the start of trading on December 19, 2024. At 11:00 AM ET on that day, Microbix intends to hold a webinar discussion of Q4 2024 results with its CEO, CFO, and COO.

read more
KOL Collaborators Present Microbix HPV Test-Control Results

KOL Collaborators Present Microbix HPV Test-Control Results

announces that key opinion leader (“KOL”) collaborators are presenting results of a Microbix Quality Assessment Product (“QAP™”) for controlling testing for high-risk types of Human Papilloma Virus (“HPV”) at the 36th annual International Papillomavirus Conference (“IPVC”) taking place in Edinburgh, Scotland, November 12 to 15, 2024.

read more
Microbix Presents Novel HSV Test Control at EMMD

Microbix Presents Novel HSV Test Control at EMMD

announces that it is presenting results of a novel Quality Assessment Product (“QAP™”) for supporting patient diagnosis and tissue analysis relating to infection with the Herpes Simplex Virus (“HSV”) at the European Meeting on Molecular Diagnostics (“EMMD”) taking place in Noordwijk, The Netherlands, October 9 to 11, 2024.

read more
Microbix Reports Continued Strong Results for Q3 Fiscal 2024

Microbix Reports Continued Strong Results for Q3 Fiscal 2024

Microbix Biosystems Inc. reports results for its third quarter and first nine months of fiscal 2024 ended June 30, 2024 (“Q3” and “YTD”) with strong revenues, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices businesses and resulting in material net income for Q3 and YTD.

read more
Q3 Fiscal 2020

Q3 Fiscal 2020

Year-Over-Year QAPs Sales Growth of 141% for Q3 MISSISSAUGA, August 14, 2020 - Microbix Biosystems Inc. (TSX: MBX, Microbix®), an award-winning life sciences innovator...

read more